Alzamend Neuro, Inc. (ALZN)

Alzamend Neuro Statistics

Total Valuation

Alzamend Neuro has a market cap or net worth of $8.36 million. The enterprise value is $4.41 million.

Market Cap	8.36M
Enterprise Value	4.41M

Important Dates

The next estimated earnings date is Monday, March 9, 2026, after market close.

Earnings Date	Mar 9, 2026
Ex-Dividend Date	n/a

Share Statistics

Alzamend Neuro has 3.80 million shares outstanding. The number of shares has increased by 985.74% in one year.

Current Share Class	3.80M
Shares Outstanding	3.80M
Shares Change (YoY)	+985.74%
Shares Change (QoQ)	+60.54%
Owned by Insiders (%)	0.02%
Owned by Institutions (%)	4.10%
Float	3.79M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.98
P/TBV Ratio	2.03
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.58

Current Ratio	6.58
Quick Ratio	6.20
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-766.93

Financial Efficiency

Return on equity (ROE) is -144.76% and return on invested capital (ROIC) is -90.36%.

Return on Equity (ROE)	-144.76%
Return on Assets (ROA)	-72.71%
Return on Invested Capital (ROIC)	-90.36%
Return on Capital Employed (ROCE)	-134.30%
Weighted Average Cost of Capital (WACC)	2.89%
Revenue Per Employee	n/a
Profits Per Employee	-$924,650
Employee Count	7
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -79.28% in the last 52 weeks. The beta is -0.25, so Alzamend Neuro's price volatility has been lower than the market average.

Beta (5Y)	-0.25
52-Week Price Change	-79.28%
50-Day Moving Average	2.18
200-Day Moving Average	3.04
Relative Strength Index (RSI)	48.32
Average Volume (20 Days)	94,418

Short Selling Information

The latest short interest is 185,292, so 4.87% of the outstanding shares have been sold short.

Short Interest	185,292
Short Previous Month	264,718
Short % of Shares Out	4.87%
Short % of Float	4.89%
Short Ratio (days to cover)	3.33

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-5.87M
Pretax Income	-5.88M
Net Income	-6.47M
EBITDA	-5.79M
EBIT	-5.87M
Earnings Per Share (EPS)	-$3.76

Balance Sheet

The company has $4.45 million in cash and n/a in debt, with a net cash position of $4.45 million or $1.17 per share.

Cash & Cash Equivalents	4.45M
Total Debt	n/a
Net Cash	4.45M
Net Cash Per Share	$1.17
Equity (Book Value)	4.37M
Book Value Per Share	1.15
Working Capital	4.00M

Cash Flow

In the last 12 months, operating cash flow was -$5.65 million and capital expenditures -$210,000, giving a free cash flow of -$5.86 million.

Operating Cash Flow	-5.65M
Capital Expenditures	-210,000
Free Cash Flow	-5.86M
FCF Per Share	-$1.54

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Alzamend Neuro does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-985.74%
Shareholder Yield	-985.74%
Earnings Yield	-73.07%
FCF Yield	-66.12%

Analyst Forecast

The average price target for Alzamend Neuro is $28.00, which is 1,172.73% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$28.00
Price Target Difference	1,172.73%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 12, 2025. It was a reverse split with a ratio of 1:9.

Last Split Date	May 12, 2025
Split Type	Reverse
Split Ratio	1:9

Scores

Altman Z-Score	n/a
Piotroski F-Score	2